Healthcare News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Strongbridge Biopharma reports key leadership appointments

Richard Kollender Strongbridge Biopharma (NASDAQ:SBBP) named Richard Kollender as COO, promoted Robert Lutz to CFO and appointed David Gill to its board, effective Sept. 3. “Continuing to assemble an experienced, multi...

August 14, 2019

Markets

HCW ups Cesca Therapeutics PT to $6.50 from $1

H.C. Wainwright raised its price target for Cesca Therapeutics (NASDAQ:KOOL) to $6.50 from $1 after the company’s second quarter revenue beat consensus. The stock closed at $3 on Aug. 13. Cesca develops and markets...

August 14, 2019

Developments

Kadmon Holdings completes enrollment for registrational GvHD trial

Kadmon Holdings (NYSE:KDMN) completed enrollment for its registrational trial of KD025 for the treatment of chronic graft-versus-host disease (cGVHD). cGvHD is a deadly complication of hematopoietic stem cell...

August 14, 2019

Developments

Moleculin Biotech completes enrollment in lymphoma clinical trial

Moleculin Biotech (NASDAQ:MBRX) has completed patient enrollment in its proof-of-concept trial of WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL). WP1220 is a topical treatment designed to inhibit p-STAT3...

August 14, 2019

Developments

Novan completes enrollment in pivotal Phase 3 molluscum contagiosum trial

Novan (NASDAQ:NOVN) has completed patient enrollment in its Phase 3 pivotal trial of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum. Molluscum contagiosum is a viral skin infection that...

August 14, 2019

Developments

Precipio posts continuous improvement in Q2 pathology sales metrics

Precipio (NASDAQ:PRPO) reported results of three key performance metrics that together demonstrate the continued growth and positive impact of the expansion of its sales force in improving pathology sales performance...

August 13, 2019

Executive Moves

BriaCell Therapeutics names Richard Berman to board

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) appointed Richard Berman to its board of directors. Mr. Berman has more than 35 years of experience in venture capital; senior management; and mergers and acquisitions. He...

August 13, 2019

Markets

HCW starts Mustang Bio at buy; PT $7

H.C. Wainwright initiated coverage of Mustang Bio (NASDAQ:MBIO) with a “buy” rating and $7 price target. The stock closed at $2.89 on Aug. 12. Analyst Joseph Pantginis writes that Mustang is developing multiple novel...

August 13, 2019

Markets

Piper cuts Ra Medical to neutral; PT to $1.50 from $9

Piper Jaffray downgraded Ra Medical Systems (NASDAQ:RMED) to “neutral” from “overweight” and slashed its price target to $1.50 from $9 after the company disclosed several operating issues in its preliminary second...

August 13, 2019

Executive Moves

Kane Biotech strengthens animal health and quality assurance team

Kane Biotech (TSXV:KNE) added to its management team, hiring Lori Christofalos as the director of quality and compliance; Shabnam Bashiri as manager of quality control; and Michel Stebenne as VP of animal health. Ms...

August 12, 2019

Markets

SVB Leerink starts Fulcrum Therapeutics at OP; PT $20

SVB Leerink initiated coverage of Fulcrum Therapeutics (NASDAQ:FULC) with an “outperform” rating and price target of $20 in 12 months. The stock closed at $11.62 on Aug. 9. Fulcrum is a clinical-stage biopharmaceutical...

August 12, 2019

Markets

HCW cuts Melinta Therapeutics to neutral and removes PT

H.C. Wainwright downgraded Melinda Therapeutics (NASDAQ:MLNT) to “neutral” from “buy” and removed its price target after the company’s chairman and CEO abruptly resigned on Aug. 9, when the stock dropped 67 cents to...

August 12, 2019

Strongbridge Biopharma reports key leadership appointments

HCW ups Cesca Therapeutics PT to $6.50 from $1

Kadmon Holdings completes enrollment for registrational GvHD trial

Moleculin Biotech completes enrollment in lymphoma clinical trial

Novan completes enrollment in pivotal Phase 3 molluscum contagiosum trial

Precipio posts continuous improvement in Q2 pathology sales metrics

BriaCell Therapeutics names Richard Berman to board

HCW starts Mustang Bio at buy; PT $7

Piper cuts Ra Medical to neutral; PT to $1.50 from $9

Kane Biotech strengthens animal health and quality assurance team

SVB Leerink starts Fulcrum Therapeutics at OP; PT $20

HCW cuts Melinta Therapeutics to neutral and removes PT

General

More